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Abstract
With the development of effective combined anti-retroviral therapy (cART), there is significant reduction in deaths
associated with human immunodeficiency virus type 1 (HIV-1) infection. However, the complete cure of HIV-1
infection is difficult to achieve without the elimination of latent reservoirs which exist in the infected individuals
even under cART regimen. These latent reservoirs established during early infection have long life span, include
resting CD4+ T cells, macrophages, central nervous system (CNS) resident macrophage/microglia, and gut-associated
lymphoid tissue/macrophages, and can actively produce virus upon interruption of the cART. Several epigenetic and
non-epigenetic mechanisms have been implicated in the regulation of viral latency. Epigenetic mechanisms such
as histone post translational modifications (e.g., acetylation and methylation) and DNA methylation of the proviral
DNA and microRNAs are involved in the establishment of HIV-1 latency. The better understanding of epigenetic
mechanisms modulating HIV-1 latency could give clues for the complete eradication of these latent reservoirs. Several
latency-reversing agents (LRA) have been found effective in reactivating HIV-1 reservoirs in vitro, ex vivo, and in vivo.
Some of these agents target epigenetic modifications to elicit viral expression in order to kill latently infected cells
through viral cytopathic effect or host immune response. These therapeutic approaches aimed at achieving a
sterilizing cure (elimination of HIV-1 from the human body). In the present review, we will discuss our current
understanding of HIV-1 epigenomics and how this information can be moved from the laboratory bench to the
patient’s bedside.
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Review
Thirty-five million people are living with HIV-1 infection
worldwide (UNAIDS, 2014). With the development of
effective combined anti-retroviral therapy (cART), mor-
tality and morbidity associated with HIV-1 has been dra-
matically reduced. cART reduces the plasma viral load
below the level of detection of classical assays. However, a
persistent residual low-level viremia is observed in most
patients using ultrasensitive RT-PCR assays [1, 2]. The
quality of life of HIV-1-infected individuals under cART
regimen is presumed to be similar to uninfected individ-
uals; however, adverse effect associated with cART is one
of the factors responsible for the non-adherence to cART
[3]. Even an interruption of cART for a period of few
weeks results in a rebound of viremia from the latent res-
ervoirs of HIV-1, and continuous interruption often leads
to AIDS. In addition, only a fraction of HIV-1-infected in-
dividuals have access to cART making the situation fur-
ther complicated (WHO) [4]. Several efforts have been
made to understand the causes and sources of viral re-
bound. Outcomes of the studies suggest the involvement
of latent reservoirs as a major source of viremia upon
cART interruption [2, 5–11].
HIV-1 primarily infects activated CD4+ T cells and
cells of monocyte/macrophage lineage. HIV-1 infection
usually results in the lysis of the CD4+ T cells, but on
rare occasions, these cells can survive long enough to re-
vert back to a resting memory state [12]. These cells
have a long life span and contribute to the persistence of
HIV-1 in the infected individuals. On the other hand,
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macrophages are resistant to cytopathic effect of the
virus, and due to their presence in diverse anatomical
sanctuaries, they further strengthen the viral persistence.
For instance, central nervous system (CNS) is one of the
anatomical sanctuaries for HIV-1 latent reservoir. CNS
resident macrophages such as meningeal macrophages,
perivascular macrophages, macrophages of the choroid-
plexus, and microglia are derived and continuously re-
placed by the migration of monocytes through blood
brain barrier [13, 14]. These CNS resident macrophages
are susceptible to HIV-1 infection and are largely re-
sponsible for HIV-1 associated dementia [15, 16]. The
presence of integrated proviral DNA has been also de-
tected in astrocytes [17]. During the late course of HIV-
1 infection where CD4+ T cells are largely depleted, CNS
resident HIV-1-infected cells might represent the source
of viral persistence in the infected individuals.
In addition to CNS, the gut plays a pivotal role in the
pathogenesis of HIV-1 in patients under cART. HIV-1
transcripts, proviral DNA, and latently infected cells
have been isolated from gut-associated lymphoid tissue
(GALT) [18–22]. Of note, recently, Rothenberger et al.
demonstrated that the viral rebound on treatment inter-
ruption is evident at multiple sites with a highly complex
and genetically diverse population of virions and sug-
gested GALT as an important latent reservoir [23]. Simi-
larly, the role of gut-associated macrophages in HIV
pathogenesis has been also postulated [24]. In the pres-
ence of stroma-derived growth factors, HIV-1-infected
monocytes can be differentiated into macrophages of
lamina propria and could represent a HIV-1 latent reser-
voir [10, 25].
The mean frequency of latently infected cells in patients
on cART, estimated with the viral outgrowth assay, is ex-
tremely low (∼1/106 resting CD4+ T cells) [26]. These latent
reservoirs consist of cells carrying “replication competent,
transcriptionally and translationally silenced, extremely
stable proviruses” capable of producing virions upon vari-
ous cellular stimuli [2, 27]. HIV-1 latency has been charac-
terized to large extent in CD4+ T cells and to less extent in
monocytes/macrophages [2, 10, 11, 28]. The latency is
broadly classified into pre and post integration latency [29].
In post integration latency, the integrated proviral DNA is
silenced in the target cells by various epigenetic and non
epigenetic mechanisms [30, 31]. Epigenetic factors include
repressive chromatin structure at HIV-1 promoter by the
interplay of several DNA and histone-modifying enzymes.
In addition, a growing list of evidences also suggests the re-
lationship between microRNAs and host epigenetic ma-
chinery. In the present review, we will limit the discussion
to the epigenetic mechanisms responsible for HIV-1 post
integration latency and how these mechanisms can be tar-
geted by anti-HIV drugs developed for purging the latent
reservoir from HIV-1-infected individuals.
HIV-1 preferential integration into the host chromatin
Several studies showed the preferential integration of
HIV-1 DNA into the euchromatin of the host chromatin
in vitro [32, 33] and in vivo [33, 34] suggesting the epi-
genetic silencing of the provirus. For instance, Han and
colleagues explored the integration site in resting CD4+
T cells populations isolated from HIV-infected individ-
uals under cART regimen. They investigated 74 integra-
tion sites from 16 patients, out of which 93 % resided
within transcription units, usually within introns. Inte-
gration was random with respect to transcriptional
orientation relative to the host gene and with respect
to position within the host gene [34]. Similar findings
have been also reported in monocyte-derived macro-
phages (MDMs) [35].
Taken together, these studies suggest the non-random
distribution of HIV-1 integration sites in the host gen-
ome suggesting the collective efforts of host and viral
factors. For example, the lens epithelium-derived growth
factor (LEDGF/p75) has been found as an important cel-
lular factor responsible for guiding the pre-integration
complex (PIC) to the host chromatin via interaction
through integrase (IN) [36–38]. Recently, data from
Debyser’s research team suggest the uptake of LEDGF/
p75 in the viral particles mediated by IN/pol and specific
cleavage by HIV protease [39].The biological relevance of
LEDGF/p75 within HIV-1 virion is under investigation
[39]. How HIV-1 integration occurs in transcriptional ac-
tive region has been studied during the last few years.
Ocwieja and colleagues observed that the knockdowns of
nuclear pore protein RanBP2 and transportin-3 altered in-
tegration targeting for HIV in HEK 293 T cells suggesting
a link between nuclear pore entry and HIV-1 integration
events [40]. A recent study by Marini and coworkers fur-
ther unfold the mystery of non-random distribution of
HIV-1 integration sites in the host chromatin of CD4+ T
cells [41]. They reported that HIV-1 integration occurs in
the outer shell of the nucleus in close correspondence with
the nuclear pore. They also showed that functional viral
integrase and the presence of the cellular Nup153 and
LEDGF/p75 integration cofactors are indispensable for the
peripheral integration of the virus [41].
Integration of HIV-1 into the transcriptional units and
their subsequent silencing suggests the involvement of
transcriptional interference (TI) in the regulation of viral
latency. TI refers to the direct inhibitory effect of tran-
scription of one gene on another gene transcriptional
process present in cis [42]. The assembly of RNA poly-
merase complex on integrated HIV-1 5′LTR might be
prevented by ongoing transcription of the host gene.
The phenomenon of TI has been shown in several cell
lines harboring proviral DNA [43–45]. In addition, the
role of chromatin reassembly factors (CRFs) has been
postulated in regulating the viral gene expression [46].
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HIV-1 promoter: center of HIV-1 epigenomics
HIV-1 viral promoter also called 5′LTR (long terminal
repeat) is one of the well-characterized viral elements so
far (reviewed in [2]). The 5′LTR has unique blend of ro-
bust TATA box, a potent initiator sequence, and binding
sites for several transcription factors including nuclear
factor kappa B (NF-kB), SP-1, AP-1, LEF-1, COUP-TF,
USF, Ets1, and CREB [47–49]. Several studies demon-
strated the formation of heterochromatin structure at
5′LTR of the integrated HIV-1 in different HIV-1 model
latent cell lines. Verdin and Van Lint described the nu-
cleosomes organization at 5′LTR in ACH-2 and U1 cell
lines under low and high transcription rates. At 5′LTR,
there are two precisely positioned nucleosomes named
nuc-0 and nuc-1 separated by two nucleosomes free re-
gion designated as enhancer/promoter element and a
regulatory region termed as HS4 [47]. Nuc-0 is located
upstream of the modulator region on HIV-1 whereas
nuc-1 is located downstream of the viral promoter and
cis acting elements [8, 47].
Histone modifications and HIV-1 post integration latency
Eukaryotic gene expression is largely influenced by
chromatin condensation/decondensation [50]. The lightly
packed form of chromatin is called euchromatin as op-
posed to the tightly packed form named heterochromatin.
The chromatin condensation status can be modulated
through a variety of mechanisms, including post transla-
tional covalent modifications of histone tails and recruit-
ment of repressive factors on methylated DNA [2]. These
modifications influence gene expression patterns by dir-
ectly altering chromatin packaging and by generating in-
teractions with chromatin-associated proteins. Of note,
integrated HIV-1 is subjected to the same chromatin regu-
lations as for any other cellular genes. An array of DNA
and histone modifying enzymes has been described as able
to be involved in the latent state of proviral DNA in in-
fected cells.
Histone modifications via methylation and acetylation
are well-studied post translational protein modifications
involved in regulating HIV-1 latency. These modifica-
tions at a particular residue of histone tails can alter ac-
cessibility of the transcription factors, viral and RNA
polymerizing machinery to the HIV-1 5′ LTR [51]. His-
tone reversible acetylation is governed by the activity of
histone acetyltransferases (HATs) and histone deacety-
lases (HDACs) (reviewed in [2, 52]). HATs add acetyl
group to the ϵ-amino group of lysine residues in histone
tails which generally result in active gene expression and
compete with HDACs that blunt transcription by redu-
cing accessibility of DNA templates [53, 54]. In cells har-
boring silenced proviruses, HDACs are recruited to
HIV-1 5′ LTR by host factors including late SV40 factor
(LSF), ying-yang 1 (YY1), NF-kappaB p50 resulting in
hypoacetylation of nuc-1 and configuring the nuc-1 to
repressive state [55]. For example, the host factor COUP-
TF interacting protein 2 (CTIP2) recruits HDAC1 and
HDAC2 to the 5′LTR of viral promoter in monocytes/
macrophages [56, 57]. The treatment of latent model cell
lines or resting CD4+ T cells isolated from HIV-1 infected
patients with HDAC inhibitors (HDACi) results in the in-
duction of HIV-1 transcription [49, 58–61] further
strengthening the role of HDAC in the establishment of
viral latency.
Histone and DNA methylation
In addition to histone acetylation-deacetylation, revers-
ible histone methylation is also known to play a role in
HIV-1 latency in CD4+ T cells and cells of myeloid
lineage. Several studies reported silenced proviral DNA
with the tri-methylation of histone H3 lysine at position
9 and 27 (H3K9me3, H3K27me3) [56, 57, 62, 63] or
dimethylation at lysine 9 (H3K9me2) [64]. These histone
modifications result in the condensation of HIV-1 asso-
ciated nucleosome (nuc1) and thus favor the repression
of HIV-1 gene expression. Benkirane and coworkers
showed the involvement of Suv39H1 (a histone lysine
methyltransferase (HMT)) and HP1 gamma in H3K9me3
and provirus silencing in several cell lines and periph-
eral blood mononuclear cells (PBMC) isolated from
HIV-1-infected patients [62]. Data from Rohr research
team further elucidated the involvement of CTIP2 in
the recruitment of Suv39H1 to the 5′LTR resulting in
H3K9me3 followed by recruitment of HP1-gamma to
the viral promoter, formation of heterochromatin, and
ultimately HIV-1 silencing in microglial cells [56, 57].
The list of HMTs involved in the regulation of HIV-1
provirus silencing has been growing. For instance, G9a, a
HMT, has been shown to promote transcriptional latency
of HIV-1 by governing H3K9me2 and formation of repres-
sive chromatin structure at 5′LTR in ACH2 and OM-10.1
cell lines [64]. Similarly, Friedman and colleagues reported
the presence of HKMT enhancer of zeste homolog 2
(EZH2) at the silenced 5′LTR in T cell line [65]. EZH2
methyltransferase, a key component of polycomb repres-
sive complex 2 (PRC2), is responsible for the H3K27me3.
Interestingly, they observed 5 and 40 % induction in HIV-
1 transcription upon SUV39H1 and EZH2 knockdown,
respectively, suggesting the prominent role of EZH2 in the
regulation of viral latency [65].
DNA methylation is one of the well-studied epigenetic
mechanisms in mammals responsible for genomic im-
printing, transposon silencing, and differential gene ex-
pression [66]. The link between HIV-1 proviral DNA
methylation and transcriptional latency is not well charac-
terized and often with contrasting studies. Kauder and
colleagues reported the methylation of two CpG islands
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flanking viral transcription site and association of methyl-
CpG binding domain protein 2 (MBD2) and HDAC2 in
one of CpG islands in Jurkat cells and HIV-1 latently
infected primary CD4+ T cells [67]. The role of HIV-1 pro-
virus methylation has been suggested in promoting la-
tency as a late event of latency establishment and could be
an additional latency control in addition to histone modi-
fications. Blazkova and colleagues reported high level of
DNA methylation in HIV-1 promoter and enhancers in la-
tent reservoir isolated form HIV-1-infected patients with
undetectable viremia as compared to viremic patients
[68]. Recently, high level of DNA methylation has been re-
ported in PBMCs infected with HIV-1 suggesting DNA
methylation as one of the strategies employed by HIV-1 in
transcriptional gene silencing [69]. However, several
contradictory findings have been also reported. For in-
stance, a study conducted on resting CD4+ T cells isolated
from aviremic individuals receiving cART revealed rare
methylation of HIV-1 proviral DNA [70] suggesting DNA
methylation may not be a prominent mechanism respon-
sible for HIV-1 latency. Taken together, further studies
deciphering the status of DNA methylation of HIV-1
proviral DNA are required in large cohorts of patients to
derive a meaningful conclusion.
Non-histone epigenetic modifications and HIV-1 post
integration latency
Similar to histone proteins, several non-histone proteins
which play an important role in HIV-1 transcription are
subjected to reversible acetylation and deacetylation [6].
For instance, p300 and CBP acetyltransferase (a member
of HATs family) acetylate the NF-kB subunit Rel A/pp65
at lysine residue 218, 221, and 230 [71, 72] and conse-
quently influence not only the DNA binding capacity of
this transcription factor but also its ability to interact
with IkappaBalpha (IκBα) and ultimately HIV-1 gene ex-
pression [6]. The deacetylation of Rel A mediated by
HDAC3 and SIRT1 results in the inhibition of HIV-1
gene expression [71, 72]. HDAC3 and SIRT1 deacetylate
RelA/pp65 at lysine residue 221 [71, 72] and 310 [73],
respectively. The HIV-1 Tat trans-activator is another
non-histone protein acetylated by p300, a necessary step
in Tat-mediated transactivation, and deacetylated by
SIRT1 in vitro and in vivo [74, 75]. The reversible acetyl-
ation of Tat is one of the mechanisms of HIV-1 latency
regulation [74, 75].
“Epigenetic drugs” and HIV-1 reactivation as a therapeutic
strategy
Aberrant epigenetic signatures have been reported in
several kinds of human pathologies including cancer
[76]. The aberrant epigenetic patterns can be corrected
by treatments with “epigenetic modifiers” or “epigenetic
modifying agents” [77] that are in clinical trials of vari-
ous phases [76]. The understanding of epigenetic mecha-
nisms associated with the viral latency promotes the
development of “epigenetic modifiers” as potential drugs
to hopefully eradicate HIV-1 from the infected individ-
uals (sterilizing cure) but more probably to decrease the
size of the HIV-1 reservoirs to a level controllable by the
host immune system (remission or functional cure).
“Kick and Kill” or “shock and kill” [78] is one of the
most discussed and tested therapeutic strategy among
HIV-1 scientists. “Kick and kill” refers to the induction
of latent proviral by various latency reversing agents
(LRAs) followed by the elimination of the infected cells
by the immune system or by cell lysis induced by viral
cytopathic effect and prevention of new infection by
cART [5] (Fig. 1). Ideally, LRAs should have permissible
toxicity and should not cause a robust and global T cell
response [8]. Several “epigenetic modifying agents” in-
cluding inhibitors of HDAC, HMT, and DNMT have
been employed in activating latent reservoir in vitro and
ex vivo (Table 1). Recently, pioneering studies have pro-




HDAC inhibitors (HDACis) are the most studied LRAs.
They have been implicated in anticancer research. More
than 10 HDACis are tested in various phases of clinical
trials for several human pathologies. Vorinostat (SAHA)
and valproic acid (VPA) have been approved by food
and drug administration (FDA) for treatment of cutane-
ous T cell lymphoma and neuropsychiatric disorders/epi-
lepsy, respectively [8, 79]. In addition to their low toxic
profile, they do not cause a global T cell activation and
therefore represent attractive therapeutic molecules [80].
HDAC inhibitors induce HIV-1 expression in la-
tently infected T cells, monocytic cells, and in resting
CD4+ T cells isolated from HIV-1-infected individuals
as reported previously [58, 81–84]. For instance vori-
nostat has been shown to reactivate HIV-1 in cells
derived from infected patients [81, 85, 86]. In addition, in
a clinical trial, a single dose of vorinostat has been re-
ported to increase cell-associated unspliced HIV-1 RNA
levels within resting CD4+ T cells and to increase simul-
taneously global acetylation [87]. Furthermore, other clin-
ical trials on patients under cART regimen with HDACi
vorinostat, panobinostat, and romidepsin have been
reported or are ongoing [2, 84, 88, 89] (Table 1).
Besides, several other HDACis including sodium
butyrate, trichostatin A, oxamflatin, scriptaid, and
entinostat have been tested in various cellular models;
however, most of them never enter into a clinical trial
[84] (Table 1).
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Recent data from Siliciano’s laboratory highlighted the
limitation of current latency reversing assay for the
evaluation of efficacy of LRAs. They found that except
bryostatin-1, none of the LRAs involved in the study
(vorinostat, romidepsin, panobinostat, disulfiram, and
bryostatin-1) was able to induce the viral outgrowth
from the cells isolated form HIV-1-infected aviremic
cART-treated patients (Table 1) [90]. There is scarcity of
data suggesting the activation of HIV-1 expression upon
HDACi treatment in MDMs derived from HIV-1-infected
individuals. Interestingly, Jønsson and coworkers reported
that romidepsin was able to prevent the de novo infection
of PBMCs and CD4+ T cells but not in MDMs in vitro
[91] and reminded that a complete eradication is only pos-
sible by considering all latent reservoirs together.
Histone methyltransferase inhibitors
Histone methyltransferase inhibitors (HMTs) are other
well-studied epigenetic players involved in the mainten-
ance of HIV-1 latency. Various HMTs such as SUV39H1,
G9a, and EZH2 are known to play important role in
proviral silencing in the latent reservoir. Several studies
demonstrated the reversal of HIV-1 latency upon the in-
hibition of G9a [64, 65, 92, 93], SUV39H1 [92, 93], and
EZH2 [65] in model cell lines and cells derived from pa-
tients (Table 1). In addition, the treatment of primary
resting CD4+ T cells with GSK343 (an effective and se-
lective EZH2/EZH1 inhibitor) resulted in reduction of
H3K27me3 mark at HIV LTR in the absence of in-
creased proviral expression. Moreover, subsequent treat-
ment of primary resting T cells with HDACi (SAHA or
vorinostat) induced a HIV-1 viral production [94]. In
combination with HDACi, HMTi could be a therapeutic
partner for purging latent HIV-1 reservoirs.
DNA methyltransferase inhibitors
Several molecules interfering with the DNA methyl-
transferase activity are in various phases of clinical trials
dealing with several kinds of cancers [76, 95, 96]. For in-
stance, Fernandez et al. assessed the combinatorial effect
of 5-aza-2′deoxycytidine (Aza-CdR), a DNA methyl-
transferase inhibitor (DNMTi) and TNF alpha in J-Lat
cell lines (6.3, 8.4, 9.2, 10.6), ACH2, J1.1, and U1 cell
lines. They observed that among J-Lat cell lines except
Fig. 1 Targeting latent HIV-1 reservoirs. HIV-1 primarily infects CD4+ T cells and cells of monocyte/macrophage lineage. Viral latency has been
extensively studied in CD4+ T cells and to some extent in monocytes/macrophages, microglia , and gut-associated lymphoid tissue macrophages.
These latent reservoirs represent the key issue pertaining to the complete eradication of HIV-1 from the infected individuals. According to “kick
and kill” strategy, virus can be activated in these reservoirs using a range of latency reversing agents which include HDACis, HMTis,
DNMTis, PKC agonists, and several other small molecules. Impact of these LRAs has been well studied in CD4+ T cells and to lesser
extent in the cells of monocyte/macrophage lineage. Upon reactivation, latent virus undergoes robust replication resulting in production
of enormous amount of virus which can induce the lysis of target cells or infected cells can be recognized by the cellular immune clearance
machinery. In addition, fresh infection should be stopped by cART. The impact of LRAs in reactivating latent virus in the cells of monocyte/macrophage
lineage is not well studied and needs further investigations
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J89 cells and Resting CD4+
T cells
Induce acetylation of histone H3K4,
H4K4 resulting in remodeling of nuc-1
In vitro, ex vivo and




J-Lat cell lines and U1 cells,
patient derived cells
Formation of euchromatin at HIV-1 5′LTR
and reactivation of HIV-1 transcription
In vitro, ex vivo, and




CD4+ T cells Formation of euchromatin at HIV-1 5′LTR
and reactivation of HIV-1 transcription
Phase 1/2 clinical trial [136]
Romidepsin HDAC
inhibitor
CD4+ T cells Formation of euchromatin at HIV-1 5′LTR




CD4+ T cells, ACH2, and J-lat
cell lines
Formation of euchromatin at HIV-1 5′LTR
and reactivation of HIV-1 transcription
In vitro, ex vivo [138, 139]
M344 HDAC
inhibitor





CD4+ T cells, J-Lat cell lines,
ACH2 and U1 cells
Increases histone acetylation resulting
in transcriptional activation of HIV-1
promoter
In vitro [58, 141]
Trichostatin A HDAC
inhibitor
CD4+ T cells, ACH2, and J49 cells Increases histone acetylation resulting
in transcriptional activation of HIV-1
promoter
In vitro, ex vivo [49, 139]
Oxamflatin HDAC
inhibitor
J89GFP and A7 cell Increases the acetylation level of
histone H3 and histone H4 at the
nucleosome 1(nuc-1) site
In vitro [59, 142]
Scriptaid HDAC
inhibitor
J89GFP and A7 cells Promotes hyperacetylation of histone In vitro [59, 143]
Givinostat (ITF2357 ) HDAC
inhibitor
J89GFP, ACH2 and U1 cells Induces hyperacetylation of histone In vitro [59, 144]
CG05/CG06 HDAC
inhibitor
ACH2 cells Induces hyperacetylation of histone In vitro [145]
Chaetocin HMT inhibitor Resting CD4+ T cells isolated
from HIV infected patients,
ACH-2, OM10.1 cells, infected
Jurkat-tat cells
A Suv39H1 inhibitor, induces loss of
H3K9me3
In vitro, ex vivo [64, 92, 93]
BIX-01294 HMT inhibitor ACH-2 and OM10.1 cells A G9a inhibitor, promotes repressive
H3K9me2
Ex vivo [64, 93]
3-deazaneplanocin A HMT inhibitor Latently infected Jurkat E4
and G4 cells





DNMTI ACH-2 cells, U1 cells, and J-Lat
cell lines
Inhibits of cytosine methylation and
prevent the recruitment of MBD2
and HDAC2 to the 5′LTR
In vitro [97]
Prostratin PKC agonist Patient derived CD4 + T cells,
J-Lat cell lines
Activates NF-KB Ex vivo [146, 147]
Phorbolmyristate
acetate (PMA)
PKC agonist J-Lat cell lines Activates NF-KB Ex vivo [146, 147]
Diterpene ester
ingenol-3-angelate
PKC agonist U1 cells Activates NF-KB In vitro [148]
Bryostatin-2 PKC agonist CD4+ T-cells, J-Lat cell lines, U1
and OM10.1 cells
Activates NF-KB In vitro, ex vivo [149, 150]
JQ1 Unclassified
agents
CD4+ T cells derived from patient,
J-Lat cell lines, U1, ACH2, and
OM10.1 cells
Releases BRD4 from the 5′LTR
and allows Tat-mediated recruitment
of P-TEFb to the 5′LTR.





J-Lat cell lines, primary CD4+
T cells
Releases BRD4 from the 5′LTR and
allows Tat-mediated recruitment of




CD4+ T cells Reactivates latent HIV-1 expression
through depletion of the
phosphatase and tensin homolog.
Ex vivo, clinical trial [113–115]
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for J-Lat 10.6, Aza-CdR plus TNF alpha activated HIV at
least twice as compared to TNF alpha. On the other
hand, in J-Lat10.6 cell line, Aza-CdR plus TNF alpha
combination moderately decreases viral activation as
compared to TNF alpha alone (Table 1). In contrast, in
ACH-2, U1, and J1.1 cells, TNFalpha stimulation with
Aza-CdR treatment resulted in a decreased HIV-1 pro-
duction as compared to the treatment with TNFalpha
alone [97]. Similarly, Kauder and colleagues reported the
synergism between TNFalpha and Aza-CdR in multiple
J-Lat cell lines (J-Lat 6.3, J-Lat 8.4, J-Lat 9.2, and J-Lat
15.4) [67]. Taken together, these results suggest a differ-
ential impact of DNMT inhibitors on different HIV-1-
infected cellular targets and should be further tested ex
vivo in latently infected primary cells derived from
patients.
Other latency reversal agents
HIV-1 latency is a multifactorial phenomenon involving
epigenetic machinery and is also subjected to “indirect”
epigenetic mechanisms. Besides “direct epigenetic modi-
fiers,” several other molecules have been tested and found
effective in recovering HIV-1 from latent reservoirs.
Interleukins (IL) -2 [98] can reverse HIV-1 latency in
infected patients but with limited success. On the other
hand, IL-7 increases viral production in productively in-
fected cells without disrupting the latency [99]. In a clin-
ical trial, patients receiving IL-2 were found to have low
number of latent cells; however, rebound viremia was
observed upon cessation of IL-2 treatment [98]. Other
potent molecules have been tested for their potential as
LRAs. For instance, protein kinase C (PKC) agonists
such as phorbol myristate acetate, prostratin, ingenol B
are known to induce the HIV-1 expression in latently in-
fected T-cell lines, monocytic cell lines, and patients-
derived primary cells [100, 101] (Table 1). Some of these
PKC agonists have either potent tumor promoting effect
or induce robust global T cells activation [5, 8, 102].
Mechanisms of action of PKC agonists are quite diverse;
however, they are known to relocate active NF-kB into
the nucleus and to activate the positive transcription
elongation factor b (P-TEFb) [8]. In addition, PKC phos-
phorylates HEXIM1 which may represent one of the key
regulatory steps of P-TEFb activity [103]. One important
PKC agonist, bryostatin-1, has several advantages over
other PKC activators. Bryostatin-1 reactivates latent
reservoir without activating T cells, and its pharmaco-
logical and toxicological profile are well known [8].
Interestingly, PKC agonists are known to downregu-
late the expression of CD4 receptor and coreceptor in
uninfected cells whereas act as LRA in latent reser-
voirs. Therefore, treatments with PKC agonists in one
hand can reactivate the HIV-1 in infected cells and
on the other hand can prevent the new infections [2,
8]. In contrast, Contreras and colleagues reported that
the inhibition of PKC delta restricts the replication of
R5-tropic viruses in MDMs [104].
Another protein that has gained considerable attention
in the last decade is bromodomain-containing protein 4
(BRD4) [105], a double bromodomain that competes
with the viral protein Tat for the binding of the P-TEFb
complex necessary for the efficient transcription of pro-
viral DNA [105–107]. Indeed, HIV-1 Tat protein recruits
P-TEFb complex to the 5′LTR resulting in the phos-
phorylation of C-terminal domain of RNA polymerase II
and efficient transcription elongation [106, 108]. Inhib-
ition of BRD4 by the selective inhibitor JQ1 has been
shown to activate HIV-1 transcription in resting CD4+ T
cells isolated from patients under cART but also in la-
tently infected monocytic and T cell lines [109]. JQ1 re-
leases BRD4 from the 5′LTR and allows the Tat-
mediated recruitment of P-TEFb to the 5′LTR [110].
Several other BRD4 inhibitors including I-Bet, I-Bet151,
and MS417 have been shown able to reactivate HIV
from latency in T cell lines and primary T cells [111].
Moreover, Boehm and colleagues found that knockdown
of BRD2, another bromodomain containing protein, re-
sulted in reversal of latency and could be used as a novel
therapeutic target [111].
Disulfiram (bis(diethylthiocarbamoyl) disulfide) (DSF),
an inhibitor of acetaldehyde dehydrogenase, is a FDA
approved compound used to support the treatment of
chronic alcoholism by producing an acute sensitivity to
ethanol [112]. DSF reactivates HIV-1 in several model
latent cell lines and primary CD4+ T cells without acti-
vating T cells [113, 114] via Akt pathway through deple-
tion of PTEN [114]. In a recent clinical trial, treatment
with DSF does not reduce the size of latent reservoir in
patients under cART regimen [115]. Of note, one of the
limitations of all these so far tested LRAs including “epi-
genetic modifiers” is their non-specificity towards la-
tently infected cells which may severely affect bystander
cells also [8].
MicroRNAs and HIV-1 latency
MicroRNAs are 20–22 nucleotide long non-coding
RNAs encoded by eukaryotic genomes, act as one of the
key regulators of post transcriptional gene regulation
[116]. In addition, several viral genomes also encode
microRNAs and also utilize cellular microRNAs to gov-
ern their pathogenesis. Role of microRNAs in contribut-
ing to viral latency has been shown in several viruses
including human cytomegalovirus [117] and HIV [118].
Bioinformatics analysis of HIV-1 genome predicted the
presence of at least 10 microRNAs [118]. Although the
presence of microRNAs in HIV-1 is still today a highly
controversial issue, however, accumulating evidences
suggest the presence and biological relevance of microRNAs
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in HIV-1 pathogenesis [119–125] and in enforcing latency
[123, 124]. For instance, Klase and colleagues demon-
strated the presence of viral microRNA derived from the
processing of HIV-1 TAR element by Dicer enzyme.
Furthermore, they detected the presence of TAR derived
microRNA in infected CD4+ T cells which could repress
the expression of viral genes through transcriptional
gene silencing [126]. In another instance, Ouellet and
colleagues suggested the biogenesis of two microRNAs
(miR-TAR-5 p and miR-TAR-3p)derived from the TAR
element upon asymmetrical processing by Dicer in
HIV-1 infected cell lines and CD4+ T cells infected with
HIV-1 [127].
Not only viral microRNAs participate in enforcing la-
tency, but cellular microRNAs also play a pivotal role in
governing viral latency. For example, high levels of micro-
RNAs (miR-28, miR-125b, miR-150, miR-223, and
miR382) have been reported in resting CD4+ T cells as
compared to the activated CD4+ T cells. The silencing of
these microRNAs with anti-sense inhibitors resulted
in increased viral production in latent cell lines and
resting CD4+ T cells [116]. Interestingly, the role of
these microRNAs in HIV-1 infectivity of monocytes is
also suggested. The lower susceptibility of monocytes
and higher susceptibility of macrophages for HIV-1
infection is also linked with the high and low expres-
sion of these microRNAs in monocytes and macro-
phages, respectively [121, 123, 128].
Similarly, the expression of miR-198 is reported to be
downregulated during monocytes differentiation into
macrophages [129]. MiR-198 does not target the viral
transcripts but targets HIV-1 Tat cofactor, cyclin T1, and
overexpression of miR-198 in macrophages suppresses
HIV-1 replication [129]. The expression of miR-198 is
quite low in resting CD4+ T cells [130]. In resting CD4
+T high levels of microRNAs targeting cyclin T1 tran-
script such as miR-27b, miR-29b, miR-150, and miR-223
have been reported [130]. Another Tat cofactor, P300/
CBP-associated factor (PCAF) is targeted by the polycis-
tronic miRNA cluster miR-17/92. In addition, HIV-1
actively suppresses the expression of this microRNA
cluster in latent cell lines and PBMCs-isolated form
HIV-1-infected patients [131]. In monocytes, high ex-
pression of microRNAs (miR-15a, miR-15b, and miR-16)
suppresses the expression of purine-rich element bind-
ing protein α, another Tat cofactor [132]. The expression
of another microRNA miR-29a has been shown to cor-
relate inversely with HIV replication in vitro and ex vivo
[133]. More recently, role of microRNA-155 is shown in
regulating latency in vitro [134]. Taken together, the
emerging data suggest that the microRNAs regulate the
HIV-1 latency by directly targeting viral transcripts or by
indirectly cellular factors transcripts important for viral
replication.
Conclusions
The interplay of host epigenetic players including
HDAC, HMT, and DNMT are largely responsible for the
maintenance HIV-1 latency. Latent reservoirs including
resting CD4+ T cells, monocyte/macrophage lineage,
microglia, and gut-associated lymphoid tissue macro-
phages are the main obstacle in the race for a cure of
HIV-1 infection. One of the strategies to eradicate the
virus consists of reactivating the latent reservoirs in
order to expose the latently infected cells to the immune
system and to the viral cytopathic effects while main-
taining cART to avoid new infections (“kick and kill
strategy”) (Fig. 1). Several efforts have been made in this
direction. Various molecules including epigenetic modi-
fying agents such as HDACi, HMTi, and DNMTi have
been shown to reactivate the virus in vitro, ex vivo, and
in vivo. Indeed, two clinical trials have recently demon-
strated that administration to aviremic-treated patients
of a single [87] or multiple [89] clinically tolerable
dose(s) of vorinostat was associated with an increase ex-
pression of cell-associated unspliced HIV-1 RNA levels
within resting CD4+ T cells in vivo. Importantly, another
recent pilot clinical trial showed that panobinostat pro-
duced not only an increase of plasma HIV genomic
RNA level but also a transient decrease in total HIV
DNA level in cART treated patients. In addition to epi-
genetic modifying agents, several small molecules such
as JQ1 and PKC agonists are able to reactivate the latent
reservoirs. Each of these agents has their own merits
and demerits and not only short- and long-term toxic-
ities but also anti-latency activities on the various viral
reservoirs have to be considered in order to develop
such LRAs. Indeed, most of the mechanistic and clinic-
ally relevant data of HIV-1 epigenomics has been derived
from CD4+ T cells and to lesser extent from monocytes/
macrophages (Fig. 1). Results are encouraging and in fu-
ture optimized targeting of HIV-1 latent reservoir by
several complementary strategies could eradicate HIV-1
infection in patients.
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